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Gastrin is a pleiotropic peptide synthesized and se-
creted by G cells in the stomach, duodenum, and pan-
creas. It has been shown to exert growth-promoting
effects on the mucosa of gastrointestinal tract, in
addition to its major physiological function to stimu-
late gastric acid secretion from parietal cells in the
stomach [1]. Proton pump inhibitors (PPIs), launched
more than 20 years ago, were designed to irreversibly
block proton pumps of parietal cells and are the most
effective drug for treating acid-related diseases. PPIs
are also used to treat peptic ulcer disease and acid
reflux-associated esophagus disease. Moreover, PPIs
are relatively safe, with very few side effects; hyper-
gastrinemia is one of the most common side effects.
Long-term use of PPIs was reported to increase the
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Proton pump inhibitors (PPIs) are the most potent anti-acid agents and are extensively used
worldwide. PPI-induced hypergastrinemia is one of the very few side effects associated with
these drugs. However, because hypergastrinemia is related to the occurrence of colonic adeno-
matous polyps, the purpose of this study was to analyze the relationship between the occurrence
of gastrointestinal polyps and hypergastrinemia induced by PPIs. This study included 259
patients who underwent colonoscopy and esophagogastroduodenoscopy between January and
August 2007. Chart records, including medication history and fasting plasma gastrin level, were
reviewed and analyzed. Any subtle polypoid lesions in the stomach and colon were sampled by
biopsy for histological examination. Helicobacter pylori infection status was examined by a rapid
urea test during esophagogastroduodenoscopy. All patients underwent endoscopy examina-
tions. A total of 122 patients were receiving PPI treatment for either peptic ulcer disease or reflux
esophagitis and were included as the study group. The remaining 137 patients were not treated
with PPIs and served as the non-PPI group. The mean fasting gastrin level in PPI users versus
non-PPI users was 121.8 ng/L versus 56.8 ng/L, respectively (p < 0.001). Although the prevalence
of gastric gland polyps was higher in the PPI group (65.6% vs. 37.2%, p < 0.001), there was no dif-
ference in the prevalence of colonic adenomatous polyps observed (22.13% vs. 22.62%, p = 0.928).
In conclusion, the prevalence of gastric polyps, particularly fundic gland polyps, was higher
among PPI users. However, the prevalence of colonic polyps was not affected by PPI use, regard-
less of past history of colonic adenomatous polyps.
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serum gastrin level by 1.5–2-fold, which has raised
concerns over whether hypergastrinemia resulting
from long-term use of PPI may have adverse effects
on the gastrointestinal tract [2]. Although no obvious
neoplastic change was found in the gastric mucosa,
an increase in enterochromaffin-like cells and fundic
gland polyps was reported [3]. Numerous studies
have suggested that the proliferative effect of hyper-
gastrinemia may also affect the mucosa of the small
intestine and colon [1,3–5]. Patients with hypergas-
trinemia as a result of Zollinger-Ellison syndrome
have a higher colonic proliferation index [1]. Inter-
estingly, in some case-control studies, the prevalence
of hypergastrinemia was higher in patients with
colon cancer than in the control subjects. Because of
the possible link between hypergastrinemia and co-
lonic adenomatous polyps or colon cancer, it is likely
that hypergastrinemia is mitogenic to human colon
mucosa, and promote colonic carcinogenesis [6–11].
Conversely, gastrin gene expression was observed in
most colon cancer cell lines and in primary colorectal
carcinoma [7,8,12]. In animal models, exogenous gas-
trin or hypergastrinemia induced by high-dose PPI
increased the proliferation of normal colonic mucosa
[13]. Although the US Food and Drug Administration
has approved the long-term use of PPI in patients
with reflux esophagitis, few studies have investigated
the effect of PPI-induced hypergastrinemia on the
colonic mucosa or the incidence of colonic adenoma-
tous polyps. The aim of this study was to investigate
whether PPI-induced hypergastrinemia was associ-
ated with gastrointestinal tract polyps, particularly
colonic adenomatous polyps.
METHODS
This cross-sectional study was carried out at Kaohsi-
ung Medical University Hospital, Taiwan. All pa-
tients and controls were recruited from our Digestive
Endoscopy Center. This study was approved by the
ethics committees of our institutional review board.
Patients
Between January 2007 and August 2007, a total of 
259 subjects were enrolled in this study. These sub-
jects underwent esophagogastroduodenoscopy (EGD)
and colonoscopy. Exclusion criteria included incom-
plete colonoscopy examination, inadequate bowel
preparation, inflammatory bowel disease, newly diag-
nosed gastrointestinal malignancy, and familial colon
polyposis. Subjects with hypergastrinemia induced
by conditions other than PPI use were excluded, in-
cluding previous gastric surgery, pernicious anemia,
Zollinger-Ellison syndrome, acromegaly, and pheo-
chromocytoma. Medical records were reviewed, in-
cluding history of chronic diseases and medication
history including PPIs, non-steroidal anti-inflammatory
drugs and cyclooxygenase-2 inhibitors. An uninter-
rupted period of PPI prescription of 2 months and 
6 months was defined as continuous and long-term
PPI use, respectively.
Serological test
Five milliliters of fasting blood was taken for plasma
gastrin examination. The gastrin level was estimated
by a radioimmunoassay.
Endoscopy
EGD was performed to evaluate gastric lesions.
Helicobacter pylori infection status was examined by 
a rapid urease test. Gastric polyps were sampled by
biopsy for histological examination. Pan-colonoscopy
was performed after a complete bowel preparation
with sodium phosphate. Detailed information was
recorded for all polypoid lesions, including size and
location (cecum, ascending colon, transverse colon,
descending colon, and rectosigmoid colon). Biopsy
was obtained for histological examination.
Statistical analysis
Qualitative parameters were analyzed using the χ2
test and Fisher’s exact two-sided tests. Analysis of
variance was performed to compare the variations
between the patient and control groups. A p value of
< 0.05 was considered statistically significant. Data
were analyzed with SPSS version 13.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
A total of 259 subjects were included in this study, and
all of them underwent EGD and colonoscopy. A total
of 122 patients used PPIs for an average duration of
21.89 months (range, 1–97 months) and 91.8% used
PPIs for more than 6 months. The control group who
had no history of PPI or H2-blocker use comprised
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137 patients. The demographic data for patients in both
groups are shown in Table 1. The PPI users were older
than the non-PPI users, because older patients often
show more co-morbidities, including peptic ulcer dis-
ease, reflux esophagitis, arthropathy, and cardiovas-
cular disease.
The prevalence of H. pylori infection was lower 
in both groups compared with general population
because most of these patients had previously re-
ceived H. pylori eradication therapy for peptic ulcer
disease, particularly in the PPI user group. Further-
more, most of the patients in the PPI user group had
received continuous PPI treatment, which affected the
accuracy of the rapid urease test for H. pylori infec-
tion and provided some false-negative results.
The average gastrin level was 121.8 ρg/mL and
56.8 ρg/mL in the PPI group and the non-PPI group,
respectively (p < 0.001) (Figure 1). The prevalence of
gastric polyps was higher in the PPI group than in the
non-PPI group (65.6% vs. 37.2%; p < 0.001) (Table 2).
By contrast, the prevalence of colon polyps was com-
parable in both groups (57.4% vs. 51.8%) (Table 3).
Although female sex, gastrin level, PPI use, and
negative H. pylori infection were associated with gas-
tric polyps, only female sex and PPI use were signifi-
cant risk factors in multivariate analysis (Table 2). 
We also found that longer duration of PPI use was
associated with higher incidence of gastric polyps
(Figure 2). By contrast, male sex, age, and history of
colonic adenomas were associated with colon polyps,
and age was the only significant risk factor in multi-
variate analysis (Table 3).
We further analyzed the histological type of gas-
tric polyps and colon polyps (Table 4). Fundic gland
polyps were the most prevalent gastric polyps and
Table 1. Characteristics of patients in this study*
Characteristics PPI user (n = 122) Non-PPI user (n = 137) p
Age 61.3 ± 11.2 52.5 ± 12.9 < 0.001
Sex 0.78
Male 54 (44.3) 63 (45.6)
Female 68 (55.7) 74 (54.4)
H. pylori infection 0.001
Negative 114 (93.4) 108 (78.8)
Positive 8 (6.6) 29 (21.2)
NSAID or COX-2 inhibitor use 0.020
Yes 9 (7.4) 2 (1.5)
No 113 (92.6) 135 (98.5)
Gastrin level (ρg/mL) 121.8 ± 154.2 56.8 ± 100.7 < 0.001
Gastric polyps† < 0.001
Present 80 (65.6) 51 (37.2)
Absent 42 (34.4) 86 (62.8)
Colon polyps‡ 0.440
Present 70 (57.4) 72 (51.8)
Absent 52 (42.6) 65 (48.2)
*Data presented as mean ± standard deviation or n (%). †Included inflammatory polyps, hyperplasia polyps, and fundic gland
polyps; ‡included inflammatory polyps, hyperplasia polyps, adenomatous polyps; PPI = proton pump inhibitor; NSAID = non-
steroidal anti-inflammatory drugs; COX = cyclooxygenase.
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Figure 1. Gastrin levels of patients using proton pump inhibitors
and control patients. The mean gastrin level was 112.8 ng/mL
in the proton pump inhibitor group and 56.8 ng/mL in the con-
trol group (independent t test, p < 0.001). PPI = proton pump
inhibitor.
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were significantly associated with PPI use (PPI group
vs. non-PPI group: 49.2% vs. 27.7%; p < 0.001). PPI use
was not associated with a carcinogenic effect on the
stomach. Furthermore, PPI use was not associated with
the prevalence of inflammatory polyps and hyper-
plastic polyps. No significant difference was observed
between the two groups in terms of the prevalence,
histological type and size of colonic polyps.
Table 2. Characteristics of patients with and without gastric polyps*
With gastric Without gastric 
p
Adjusted OR† 
polyps (n = 131) polyps (n = 128) (95% CI)
Sex 0.011
Female 82 60 1
Male 49 68 0.51 (0.297–0.863)
Age 57.73 ± 11.96 55.55 ± 13.80 0.176 1.00 (0.980–1.024)
Gastrin level (ρg/mL) 0.005
< 90 89 106 1
≥ 90 42 22 1.36 (0.690–2.684)
H. pylori 0.043
No 118 104 1
Yes 13 24 0.60 (0.276–1.300)
History of PPI use < 0.001
No 51 86 1
Yes 80 42 2.70 (1.488–4.928)
*Data presented as n, mean ± standard deviation; Gastric polyps included inflammatory polyps, hyperplasia polyps and fundic gland
polyps; †multivariate analysis with adjusted OR for age (continuous), gastrin level (< 90 vs. ≥ 90 ρg/mL), sex (male vs. female), 
H. pylori infection (yes vs. no) and PPI use (yes vs. no). OR = odds ratio; CI = confidence interval; PPI = proton pump inhibitor.
Table 3. Characteristics of patients with and without colon polyps*
Patients with colon Patients without colon 
p
Adjusted OR†
polyps (n = 142) polyps (n = 117) (95% CI)
Sex 0.013
Female 68 74 1
Male 74 43 1.56 (0.925–2.630)
Age 59.48 ± 11.60 53.23 ± 13.60 < 0.001 1.03 (1.012–1.056)
Gastrin level (ρg/mL) 0.399
< 90 104 91 –
≥ 90 38 26
H. pylori 0.540
No 120 102 –
Yes 22 15
PPI use 0.438
No 74 65 –
Yes 70 52
NSAID or COX-2 inhibitor user 0.544
Yes 7 4 –
No 135 113
History of colonic adenoma 0.012
No 90 89 1
Yes 52 28 1.46 (0.816–2.616)
*Data presented as n or mean ± standard deviation; Colon polyps included inflammatory polyps, hyperplasia polyps and adenoma-
tous polyp; †multivariate analysis with adjusted OR for sex (male vs. female), age (continuous) and history of colon adenoma (yes vs.
no). OR = odds ratio; CI = confidence interval; PPI = proton pump inhibitor; NSAID = non-steroidal anti-inflammatory drugs;
COX = cyclooxygenase.
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To exclude the possibility of underestimation, we
found that, of the 259 patients included in this study,
165 patients had undergone colonoscopy in our hos-
pital at least once, including 97 patients in the PPI
group and 68 patients in the non-PPI group (Table 5).
The average number of previous colonoscopy exami-
nations was 2.36 in the PPI group and 2.09 in the con-
trol group. There was no difference in the prevalence
of colonic adenomas between the two groups, even
in patients with history of colonic adenoma.
DISCUSSION
PPIs are powerful inhibitors of acid secretion and
induce hypergastrinemia [2,14]. Although the safety
concerns over PPI-induced hypergastrinemia have
been demonstrated in many studies, and are well
reviewed [3,15], few studies have investigated the
long-term effect of hypergastrinemia on colon mucosa.
Meanwhile, the effect of hypergastrinemia on the 
incidence of colorectal adenomatous polyps remains
controversial [10,11,16,17].
In animal models, hypergastrinemia has been im-
plicated as a risk factor for colon cancer. Gastrin may
induce proliferation during intestinal crypt regen-
eration following chemical or radiation injury [4].
Omeprazole-induced hypergastrinemia was shown
to increase the number of small intestinal adenomas
in APCmin–/+ mice [13]. However, in this study, the
gastrin level was 6–10-fold higher than that in the
normal population and the effect of hypergastrine-
mia may be amplified. In humans, relatively few stud-
ies have examined the effect of hypergastrinemia on
colon mucosa, particularly PPI-related hypergastrine-
mia. Two studies based on patients with Zollinger-
Ellison syndrome showed that hypergastrinemia
increased the rate of colonic proliferation but not the
prevalence of adenomas [1,18]. However, these stud-
ies did not describe the distribution of colonic ade-
nomas and or provide longitudinal follow-up with
colonoscopy. Another study analyzed 10 patients with
autoimmune gastritis and six patients with Zollinger-
Ellison syndrome, and all of them had undergone
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Figure 2. The prevalence of gastric polyps increased with longer
duration of proton pump inhibitor use (c2 test, p = 0.951).
PPI = proton pump inhibitor.
Table 4. Histological features and location of gastric
polyps and colon polyps in patient treated with proton
pump inhibitors 
PPI user Non-PPI user
p
(n = 122) (n = 137)
Gastric polyps 80 51 < 0.001
Fundic gland 60 38 < 0.001
polyps
Inflammatory 17 13 0.266
polyps
Hyperplasia 3 0 0.997
polyps
Colonic polyps 70 72 0.440
Non-adenoma* 43 41 0.365
Adenoma 27 31 0.928
Mean size (cm) 0.351 0.358
*Non-adenoma polyps include hyperplastic polyps and
inflammatory polyps. PPI = proton pump inhibitors. 
Table 5. Association between proton pump inhibitor
treatment in patients with versus without history of
colonic adenomas
PPI user Non-PPI user
p
(n = 97) (n = 68)
New adenomas 26 11 0.111
History of 48 32
colonic adenomas
Colonic adenomas 17 9 0.495
Negative finding 31 23
No history of 49 36
colonic adenomas
New colonic 9 2 0.082
adenomas
Negative finding 40 34
PPI = proton pump inhibitor.
Proton pump inhibitors and gastric polyps
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proctoscopy. This study showed that endogenous hy-
pergastrinemia enhanced the proliferation of colorec-
tal mucosa. However, it is unwise to over-interpret
the results obtained in the rectum [5]. Two large pop-
ulation-based studies in Europe revealed that long-
term PPI therapy (> 5 years) was not associated with
increased risk of colon cancer. Unfortunately, these
studies did not report the results of the colonoscopy
examination, precancerous evaluation or the gastrin
level [19,20].
In our study, hypergastrinemia was two-fold higher
in the PPI group than in the non-PPI group. The pre-
valence of gastric polyps was higher, particularly
fundic gland polyps, in the PPI group. Our results are
consistent with those of previous studies [21–23].
Moreover, we evaluated the long-term effect of PPI
on colon mucosa in patients who had used PPIs for
over 6 months. Overall, the prevalence of adenoma
was similar in both groups. Our results are consistent
with the results from population-based studies, sug-
gesting that 20–40% of patients have prevalent colonic
adenomas. We also found that neoplastic changes (tu-
bulovillus adenoma, large adenoma, and high-grade
dysplasia) were not associated with hypergastrinemia,
regardless of the history of colonic adenoma. More
importantly, our results reveal an important implica-
tion, that follow-up colonoscopy for colonic adeno-
mas may be adequate for PPI users [24,25].
However, there are several weaknesses of our
study. Selection bias may present in the patients who
visited our hospital for their first colonoscopy. Patients
who had undergone colonoscopy more than twice may
be more relevant for evaluating the effect of hyper-
gastrinemia between PPI users and non-PPI users. A
huge variation in fasting gastrin level was noted among
the PPI users. Many reasons may be attributed for
this, including age, atrophic gastritis, blood sampling
time and individual differences. One of the limitations
of our study was the lack of longitudinal analysis of
the gastrin level and assessment of gastrointestinal
polyps before and after PPI use. These problems were
also encountered in other studies. More studies are
needed to clarify the association between long-term
PPI use and effects on colonic mucosa.
In conclusion, our study showed that PPI users
are prone to have gastric polyps, including fundic
gland polyps. However, long-term use of PPIs was not
associated with increased prevalence of colon polyps,
irrespective of history of colonic adenoma. We also
showed no carcinogenic effect of PPI use on the stom-
ach and colon.
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氫離子阻斷劑使用對腸胃道息肉之影響
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氫離子阻斷劑已廣泛使用於消化性潰瘍及逆流性食道炎，然而會造成胃泌素 2–3 倍之
上升，刺激胃粘膜 enteochromaffin-like cell增生，此外也有刺激小腸及大腸黏膜
增生之作用。本研究針對自 2007 年 1 月至 2007 年 8 月在本院接受內視鏡檢查之病
患，分析血中胃泌素值。回溯分析病患過去用藥的病史及用藥時間。本研究共分析 
122 位使用氫離子阻斷劑患者，以 137 位同期接受內視鏡檢查而未使用氫離子阻斷劑
患者作為對照組。其血中胃泌素值分別為 121.8 ng/L及 56.8 ng/L （p ＝ 0.034），
具統計學差異。使用氫離子阻斷劑患者平均使用氫離子阻斷劑的時間為 21.89 個月
（1–76個月）。胃鏡檢查發現，胃瘜肉在兩組的發生率分別為 PPI user: 65.6％； 
non-PPI user: 37.2% （p < 0.001）。使用氫離子阻斷劑患者可能有較高的胃息肉發
生率，但以良性小型 fundic gland polyps居多，無增加 adenomatous polyps之影
響。大腸瘜肉的發生率分別為 PPI user: 22.13％； non-PPI user: 22.62% （p ＝ 
0.928），兩組無統計學之差異。本研究的觀察，氫離子阻斷劑未增加消化道癌症或腺
瘤之發生率。
關鍵詞：大腸瘜肉，胃瘜肉，胃泌素，氫離子阻斷劑
（高雄醫誌 2010;26:76–83）
